Schrezenmeier H - Search Results

1

mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects.

Fabricius D, Ludwig C, Scholz J, Rode I, Tsamadou C, Jacobsen EM, Winkelmann M, Grempels A, Lotfi R, Janda A, Körper S, Adler G, Debatin KM, Schrezenmeier H, Jahrsdörfer B. Fabricius D, et al. Among authors: schrezenmeier h. Vaccines (Basel). 2021 Aug 18;9(8):918. doi: 10.3390/vaccines9080918. Vaccines (Basel). 2021. PMID: 34452043 Free PMC article.

2

The K+ channel openers diazoxide and NS1619 induce depolarization of mitochondria and have differential effects on cell Ca2+ in CD34+ cell line KG-1a.

Körper S, Nolte F, Rojewski MT, Thiel E, Schrezenmeier H. Körper S, et al. Among authors: schrezenmeier h. Exp Hematol. 2003 Sep;31(9):815-23. doi: 10.1016/s0301-472x(03)00199-1. Exp Hematol. 2003. PMID: 12962728 Free article.

3

The role of mitochondrial targeting in arsenic trioxide-induced apoptosis in myeloid cell lines.

Körper S, Nolte F, Thiel E, Schrezenmeier H, Rojewski MT. Körper S, et al. Among authors: schrezenmeier h. Br J Haematol. 2004 Jan;124(2):186-9. doi: 10.1046/j.1365-2141.2003.04742.x. Br J Haematol. 2004. PMID: 14687028 Free article.

4

Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines.

Rojewski MT, Körper S, Thiel E, Schrezenmeier H. Rojewski MT, et al. Among authors: schrezenmeier h. Oncol Rep. 2004 Feb;11(2):509-13. Oncol Rep. 2004. PMID: 14719092

5

Depolarization of mitochondria and activation of caspases are common features of arsenic(III)-induced apoptosis in myelogenic and lymphatic cell lines.

Rojewski MT, Körper S, Thiel E, Schrezenmeier H. Rojewski MT, et al. Among authors: schrezenmeier h. Chem Res Toxicol. 2004 Jan;17(1):119-28. doi: 10.1021/tx034104+. Chem Res Toxicol. 2004. PMID: 14727926

6

Depolarisation of the plasma membrane in the arsenic trioxide (As2O3)-and anti-CD95-induced apoptosis in myeloid cells.

Nolte F, Friedrich O, Rojewski M, Fink RH, Schrezenmeier H, Körper S. Nolte F, et al. Among authors: schrezenmeier h. FEBS Lett. 2004 Dec 3;578(1-2):85-9. doi: 10.1016/j.febslet.2004.10.075. FEBS Lett. 2004. PMID: 15581621 Free article.

7

Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.

Rojewski MT, Körper S, Schrezenmeier H. Rojewski MT, et al. Among authors: schrezenmeier h. Leuk Lymphoma. 2004 Dec;45(12):2387-401. doi: 10.1080/10428190412331272686. Leuk Lymphoma. 2004. PMID: 15621751 Review.

8

Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.

Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin KM, Stahnke K. Mohr A, et al. Among authors: schrezenmeier h. Oncogene. 2005 Mar 31;24(14):2421-9. doi: 10.1038/sj.onc.1208432. Oncogene. 2005. PMID: 15735742

9

Immunotherapy for cancer: promoting innate immunity.

Lotfi R, Schrezenmeier H, Lotze MT. Lotfi R, et al. Among authors: schrezenmeier h. Front Biosci (Landmark Ed). 2009 Jan 1;14(3):818-32. doi: 10.2741/3280. Front Biosci (Landmark Ed). 2009. PMID: 19273102 Free article.

10

Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material.

Lotfi R, Eisenbacher J, Solgi G, Fuchs K, Yildiz T, Nienhaus C, Rojewski MT, Schrezenmeier H. Lotfi R, et al. Among authors: schrezenmeier h. Eur J Immunol. 2011 Jul;41(7):2021-8. doi: 10.1002/eji.201041324. Eur J Immunol. 2011. PMID: 21538978 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

348 results

Search Page